Evaluation of Practical Monitoring Approaches for Patients Receiving Systemic Treatment for Brain Metastases

1

This study evaluated surveillance strategies for patients treated with systemic therapy for brain metastases at a single institution.
2

Out of 33 patients, 14 received treatment that met the 2021 ASCO-SNO-ASTRO guidelines for brain metastases.
3

The median time to the first, second, and third surveillance MRI was 45, 95, and 180 days, respectively.
4

The one-year cumulative incidence of local progression was similar between guideline and non-guideline groups, at 0.43 and 0.32, respectively.
5

The study highlights the need for evidence-based guidelines for monitoring patients receiving CNS-penetrating systemic therapies.

Frontiers In Oncology

by Britney Weng, Caressa Hui, Jerica Lomax, Ahmed Mohyeldin, Nataliya Mar, Warren A. Chow, Misako Nagasaka, Jeremy Harris, Aaron B. Simon
April 20, 2026

1